Table 3. Postoperative application of ICIs in LT.
| Authors | Year | No. of patients | ICIs | Mean immunotherapy course | Immunosuppression | Mean time between immunotherapy and LT (year) | Rejection | Recurrence/outcomes |
| ICI, immune checkpoint inhibitor; LT, liver transplantation; Tac, tacrolimus; MMF, mycophenolate mofetil; N, No; Y, Yes; N/A, not available; PR, partial response; PD, progressive disease; CR, complete response; SD, stable disease. | ||||||||
| Morales et al. (67) | 2015 | 1 | Ipilimumab | 4 | Tac, MMF | 8.0 | N | PR |
| Ranganath et al. (68) | 2015 | 1 | Ipilimumab | 4 | Tac | 8.0 | N | N/A |
| De Toni et al. (69) | 2017 | 1 | Nivolumab | 7 | Tac | 0.9 | N | PD |
| Chen et al. (70) | 2019 | 1 | Pembrolizumab | 15 | Everolimus, MMF, steroids | 3.6 | N | PR |
| Varkaris et al. (71) | 2017 | 1 | Pembrolizumab | N/A | Tac | 8.0 | N | PD |
| Zhuang et al. (72) | 2019 | 1 | Nivolumab | 31 | Tac | 2.7 | N | PD |
| Qiu et al. (73) | 2020 | 1 | Camrelizumab | 5 | Steroids, MMF, Tac | 4.0 | N | PD |
| Rammohan et al. (74) | 2018 | 1 | Pembrolizumab | N/A | Steroids, MMF, Tac | 4.0 | N | N |
| Amjad et al. (75) | 2020 | 1 | Nivolumab | N/A | Tac, MMF | 1.3 | N | N |
| Jarroudi et al. (76) | 2020 | 3 | Nivolumab | 3 | Tac | 1.9 | N | PD |
| Wang et al. (77) | 2016 | 1 | Pembrolizumab | 1 | Tac, sirolimus | 1.0 | Y | N |
| Gassmann et al. (78) | 2018 | 1 | Nivolumab | 1 | Steroids, MMF, everolimus | 2.0 | Y | N/A |
| DeLeon et al. (79) | 2018 | 5 | Nivolumab | 3.2 | Tac, sirolimus, MMF | 3.3 | 1/5 Y | 3/5 PD1/5 CR |
| Lee et al. (80) | 2020 | 1 | Nivolumab | 2 | Cyclosporine, everolimus, MMF, steroids, sirolimus | 12.0 | Y | N/A |
| Shi et al. (81) | 2021 | 5 | Toripalimab | 4.2 | N/A | N/A | N | 2/5 PD1/5 SD |
| Friend et al. (82) | 2017 | 2 | Nivolumab | 1.5 | Sirolimus, Tac | 1.0 | Y | N/A |